An established ALS drug, now defended by patents about how it is taken
Shionogi Inc. is asserting up to four U.S. patents across four ANDA actions in the District of New Jersey, against Sandoz, Cipla, Azurity and Apotex, all aimed at RADICAVA ORS® (edaravone) oral suspension. The ’586 patent appears in every case. The others add layers around pharmacokinetic and administration conditions, so the contest is about more than the molecule. Cases 2:26-cv-08842, 2:26-cv-09658, 2:26-cv-09805 and 2:26-cv-11105 (D.N.J.). Based on the four identified proceedings and the supporting literature cited below. The complaints and patent claims were not reviewed for this article.
One common patent, three that come and go
The four actions are ANDA-related patent infringement suits over the same oral product. The asserted patent footprint is not the same in each. Sandoz and Azurity are each identified with the ’586 patent alone. Cipla is identified with the ’769, ’469 and ’586 patents. Apotex is identified with all four: the ’611, ’769, ’469 and ’586 patents.
| Defendant | Case number (D.N.J.) | Patents identified |
|---|---|---|
| Sandoz | 2:26-cv-08842 | ’586 |
| Cipla | 2:26-cv-09658 | ’769, ’469, ’586 |
| Azurity | 2:26-cv-09805 | ’586 |
| Apotex | 2:26-cv-11105 | ’611, ’769, ’469, ’586 |
The full numbers are U.S. Patent Nos. 12,478,611; 12,527,769; 12,569,469; and 12,599,586.
From edaravone biology to an oral formulation
The therapeutic rationale came first. The review How Is Edaravone Effective Against Acute Ischemic Stroke and Amyotrophic Lateral Sclerosis? describes edaravone as a potent free-radical scavenger and discusses the role of oxidative stress in ALS. That gave edaravone an established pharmacological basis well before any specialised oral formulation existed.
The route came next. Treeway TW001 B.V. moved beyond intravenous administration toward once or twice-daily oral dosing for ALS and other oxidative-stress-mediated neurodegenerative disorders. The disclosed approach centred on liquid aqueous edaravone formulations with defined dose, concentration and dosing-volume ranges, and it also addressed preparing the oral formulation from particulate edaravone. Human studies tied oral administration to systemic exposure and bioavailability, which made oral delivery a viable approach.
That early work was about making edaravone orally deliverable. Later developments shifted attention from the route to the physical characteristics and performance of the dosage form: particle size, suspension properties, dissolution and, finally, pharmacokinetic behaviour.
The question moved from whether edaravone can be taken orally to how that dose behaves once it is.
When meals shape drug exposure
Food effects were already a known issue in ALS pharmacotherapy. Clinical-pharmacology work on riluzole showed that a high-fat meal could substantially change systemic exposure, reducing both Cmax and AUC. The 2019 FDA Clinical Pharmacology Review for EXSERVAN® connected that effect to practical dosing. It reported reduced riluzole exposure after a high-fat meal and recommended administration at least one hour before or two hours after a meal.
These findings concern riluzole, not edaravone. They matter because they show an established principle in ALS therapy: meal composition and dosing time can change oral exposure, so the interval between eating and dosing is a real consideration for consistent pharmacokinetics. That is the technical backdrop for later efforts to define meal-dependent administration conditions for oral edaravone, where Cmax and AUC characterise exposure under fed and fasted conditions.
From formulation optimisation to administration optimisation
As oral edaravone development advanced, the innovation focus widened. It was no longer only about creating an orally deliverable formulation. It increasingly addressed how that formulation performs under real-world conditions: dissolution, systemic exposure and the influence of meals on pharmacokinetics. The intellectual property follows the same path: controlling the physical characteristics of edaravone, managing its dissolution and bioavailability, and finally defining the meal-dependent conditions under which it should be dosed.
Generic competition moves beyond the molecule
The four proceedings place formulation, pharmacokinetic and meal-dependent administration claims around one oral product. The ’586 patent is the common layer, present in all four identified cases. The ’769, ’469 and ’611 patents add protection around specific pharmacokinetic and administration conditions in selected proceedings, with Apotex facing the widest set.
| Layer | What the record shows |
|---|---|
| Therapeutic rationale | Edaravone as a free-radical scavenger, with oxidative stress implicated in ALS. |
| Oral deliverability | Liquid aqueous oral formulations with defined dose, concentration and volume, and human data on systemic exposure and bioavailability. |
| Dosage-form performance | Particle size, suspension properties, dissolution and bioavailability. |
| Food and timing | Meal-dependent administration, characterised by Cmax and AUC under fed and fasted conditions, with riluzole as the established ALS precedent for food effects. |
For an established therapy entering a more competitive stage of its lifecycle, that is a deliberate structure: an existing active ingredient surrounded by several layers of product-specific and method-of-use protection as generic entrants appear.
Two limits apply. This analysis works from the four identified proceedings and the supporting literature, not from the claim text, so it does not say which patent covers which feature or whether any ANDA product falls within any claim. And because the earlier oral edaravone and riluzole food-effect work is public, how much of the later layers was new is a question the claims and the prior art will decide, not this summary.
The competitive question is no longer only what drug is being used, but how, when and under what conditions it is delivered.
Common questions
What product is at issue in the Shionogi edaravone litigation?
RADICAVA ORS® (edaravone) oral suspension, an oral edaravone product for amyotrophic lateral sclerosis (ALS).
Which patents has Shionogi asserted?
U.S. Patent Nos. 12,478,611 (’611); 12,527,769 (’769); 12,569,469 (’469); and 12,599,586 (’586). They are not asserted in every case. Sandoz and Azurity are identified with the ’586 patent, Cipla with the ’769, ’469 and ’586 patents, and Apotex with all four.
Who are the defendants and what are the case numbers?
Four ANDA actions are identified in the District of New Jersey: Sandoz (2:26-cv-08842), Cipla (2:26-cv-09658), Azurity (2:26-cv-09805) and Apotex (2:26-cv-11105).
Which patent is common to all four cases?
The ’586 patent. The ’769, ’469 and ’611 patents appear only in selected proceedings.
Why does meal timing matter for oral edaravone?
Food can change how much of an oral drug reaches the bloodstream. For riluzole, another ALS drug, a high-fat meal reduced both Cmax and AUC, and the 2019 FDA Clinical Pharmacology Review for EXSERVAN® recommended dosing at least one hour before or two hours after a meal. That is the established principle behind later work on meal-dependent conditions for oral edaravone.
What is the broader IP strategy visible in these cases?
A progression from protecting what the drug is to protecting how it performs: molecule, formulation, performance, pharmacokinetics, then administration conditions.
Does this article say any defendant infringes, or that any patent is valid?
No. It describes the identified proceedings and the technical background around them. It makes no infringement, validity or enforceability determination, the claim text was not reviewed, and no court ruling is reported here.
